I don’t want to belittle the progress that Kraft has made in reducing the weight of its packaging but you have to ask the question, how much of this reduction is due to the move from heavy glass jars to light weight laminated pouches? 

There is no doubt that this will have had a huge positive impact on there transportation footprint, which is great – but what about the end life of the laminate pouch?  I’m still waiting to be convinced that high temperature recycling of laminates is really the right way to go.  And what about the end consumer, how many of them know how or where to recycle laminate pouches compared to those that can and do easily recycle glass jars?

Great marketing story though. (Jane Bear)

Kraft Foods has revealed it has cut 68,000 tonnes of packaging from its products around the world in the past five years.  To read the full article visit packagingnews.co.uk

As we hurtle towards the end of January (already you say????) it is time to focus the mind again on packaging legislation.

We are routinely coming across pharma companies (small & large) who just don’t keep up with or monitor changes in packaging legislation, that will have a major impact on their businesses.

A good example is Braille legislation which is now MANDATORY for ALL pharma packs sold in Europe and has to be in place (i.e. on packs on the market) within the next 7 MONTHS.

As a consequence of non-compliance, an estimated 20% of pharma companies could have their products de-listed and taken off the market. So why do companies ignore it?

The following link will take you to a very interesting and comprehensive article on the European Pharmaceutical Manufacturer (EPM) magazine website: Braille labelling on medicines packaging

This article will give you some good tips on how to ensure that you comply and a summary of it has been printed in the latest version of the EPM printed magazine. Chris Penfold

A recent Los Angeles Times article examines how an increase in counterfeit condoms in China has health officials fearing the worst — the products “may in fact spread infectious diseases, tarnishing the axiom that condoms mean safe sex.”

The newspaper continues, “Authorities estimate that up to a third of the contraceptives used in some parts of China are counterfeits, despite improvements in state food and drug oversight. None of the counterfeits are properly sterilized, and others are of such inferior quality that they could rupture during use.”

The article details how authorities are attempting to track down what they estimate are more than one million condoms distributed throughout China, and notes how the knock-off condoms were uncovered in discount stores in New York, Texas and Virginia in 2008.

Thanks to @TheBodyGlobal for bringing our attention to this article via Twitter. More articles like this can be read at: www.thebody.com

That is a large fall in profits and although it was based against a very good 2008 so a fall was expected it still doesn’t do anything to build confidence in the business.  It will be interesting to see what they do now, will they cancel any innovations they have in the pipeline to save money or will they go all out on innovation to try and push profits back up?(Jane)

Profits fell by one third for global beauty provider Beiersdorf as European consumers cut back on their beauty spend during 2009. In the face of the tough economic conditions, the company reported provisional figures showing that net income fell from €567m in 2008 to €379m, a fall of 33 per cent.

via Beiersdorf 2009 profit hit by sales downturn.

Drug approvals from the Food and Drug Administration were flat last year compared with 2008 and warnings fell, even as the agency’s new leadership struck a tougher stance on safety.

The FDA approved 26 first-of-a-kind prescription drugs last year, up slightly from 25 in 2008, according to figures from Washington Analysis, an investment research group. New drugs cleared in 2009 included Novartis’ kidney cancer drug Afinitor and Bausch and Lomb’s pink eye medicine Besivance.

Chris Penfold – there are a number of reasons froi this trend, one of them being a reduced number odf applications – so we can’t read too much in to this report.

Sourced from Pharmaceutical & Medical News, 6th January 2010 – Washington, USA

Read the full article at: Pharmaceutical & Medical Packaging News

Stockholm, Sweden — Experts from 15 countries are meeting this week to begin developing standards to cover environmental issues related to packaging such as reuse, recycling and composting.

About 70 delegates from China, Japan, Korea, the United States and 11 European countries are meeting in Sweden for the first gathering for the SC4 Packaging and Environment committee.

Published on Greenbiz.com 12th Dec 2009 and brought to our attention by our Twitter friend @packagindiva – thanks JoAnn! It would be good to get some consistency in this area. Well overdue. What to you think? Chris

The full article can be read here: http://bit.ly/4UB8ZK

I found the following article via a LinkedIn packaging group and it gives an interesting overview of size, trends, obstacles, opportunities and predictions pharma packaging industry. Have a read of the full article and let us know what you think. Chris

According to a survey conducted by Pharmaceutical Technology Europe (PTE), almost 50% of you believe that cost is the biggest limiting factor to innovation in the pharmaceutical packaging industry, while regulations were also thought to present a major hurdle to new development, accounting for almost two-thirds of the remaining votes.¹ The pharmaceutical industry recognizes the importance of good packaging design, in particular because of the continuing pressure to aid patient compliance, meet regulatory demands, and increase a brand’s life and appeal; however, manufacturers must also innovate while improving efficiency and adapting to the growing threat of drug counterfeiting.

You can read the full article here (but may need a LinkedIn account):

http://fb.me/3mDlBhX

Via LinkedIn link to Pharmaceutical Technology Europe, Volume 21, Issue 11 Nov 1, 2009
Article by: Fedra Pavlou, Stephanie Sutton, Corrine Lawrence

You may recall that we recently went on a UKTI Trade mission trip to Los Angeles to better understand the potential of the US market. Hardly a ‘normal’ week for us, but we managed to capture events as we went along and here is our summary of a fantastic adventure that worked out really well for us and certainly raised our profile! Anyone that would like a job – ‘please apply within’ Chris

My Week: Chris Penfold, of Design Cognition

Published – Tuesday, November 24, 2009, from www.thisisbusiness-eastmidlands.co.uk/

Friday: Our company, Design Cognition, provides packing development and consultancy services to the pharmaceutical industry.

We have been thinking about exporting our skills and services to the US, which represents 40% of the global healthcare market, so a trade mission to the American Association of Pharmaceutical Scientists convention in Los Angeles seems an ideal route in.

Through UKTI, we manage to secure a free Club Class flight with BA – sadly only one. I fly ‘cattle class’ whilst our chief technical officer Annie Dallison enjoys the Club lounge, Champagne reception and a top-of-the-range bed. I sit with my bag of crisps, a bottle of water and a good book.

Arriving at Los Angeles airport we are greeted by a friendly character who directs us to the hotel shuttle bus and then announces that he is a volunteer collecting for the destitute and homeless of LA. We give him a small donation.

As we enter LA, the problem facing President Obama becomes ever more apparent as we see a number of homeless sleeping rough by the roadside. It’s obvious why donations for the destitute are needed. We certainly take our NHS service for granted. Despite its many faults, we can expect a certain level of care from a system which is the envy of the world.

Saturday: Our hotel is actually a ‘motel’ with a few extras such as a pond for a swimming pool. I get the Jacuzzi in my room and Annie doesn’t, so I feel slightly vindicated after the flight arrangements.

Sunday: After breakfast we catch up with George Canty of the East Midlands Healthcare and Bioscience iNet, who is representing UKTI. He will be helping us to meet potential customers, suppliers and partners and to discuss funding with investors.

We decide to spend today on the Pacific coast at Santa Monica and Venice Beach where tea and cake at the Tudor tea rooms includes a choice of any tea from around the world, including Typhoo and PG Tips.

The afternoon is spent at the LA Convention Centre where we set up the stand for the show.

The trade mission has involved a number of our BioCity Nottingham sister companies including Pharmaceutical Development Services and Food & Drink Analytical Services. We will be sharing stand facilities for the next few days.

This evening UKTI holds a networking meeting at the ‘Scottish Pub’ so we get to know the UKTI representatives in the US.

The team get to meet The British Consul General, Dame Barbara Hay

Monday: Still ‘Sleepless in LA’ with a 4.30am awakening. I’m finding difficulty adjusting to the eight hour time difference, so I use my time productively to catch up on emails and to press my crumpled suit.

The American Association of Pharmaceutical Scientists’ exhibition doesn’t start until 12.30. It is momentarily disrupted by animal rights protestors so security levels are high. The event gets off to a good start and we have a steady stream of visitors to our stand.

The purpose for our being here is to learn as much as possible about the US market and to assess how we might help US pharmaceutical companies to better understand European pharmaceutical packaging requirements and regulations.

Tuesday: A full day at the show is followed by an evening reception hosted by UKTI and the British Consul General, Dame Barbara Hay.

We are on the 54th floor of the Wells Fargo building with fabulous panoramic views of illuminated LA. Today is my 50th birthday so it is great to celebrate in style.

In a quieter moment we get to meet Samuel L Jackson

Wednesday

I manage to sleep in until 5am as my body continues to adjust. The third day and climax of the show is slower but we attract some potential leads.

Thursday

We leave for England today and everything seems to be going according to plan.

Annie makes the most of being amongst the privileged in the Club Class environment whilst I have another sandwich. Our expectations for this trip had been modest and we hadn’t expected to come back with a ‘shed full’ of orders, but we both agree that the trip has been invaluable.

You can read the ‘This is Business’ article here: LA Article

I was amazed to hear that the ‘Max Factor‘ brand has been ‘pulled’ from the US market by Proctor & Gamble. How can that be for such a prominent brand? Are US females cutting back and going around without their ’slap’ on? or is it just that the market is so competitive in the US?….at least the brand is still available in other markets! However, there are some encouraging  ‘green shoot’ signs showing in the US (moreso than the UK in many respects) – so let’s hope that the trend continues and migrtaes across the ‘pond’! Chris

Via www.cosmeticsdesign.com 19 Nov 2009

An upturn in the US consumer products industry is likely to benefit the personal care sector as 2009 draws to an end, indicating a much stronger year ahead. Latest US GDP figures show a growth rate of 3.5 percent for the third quarter, a figure that is likely to translate into the creation of more jobs and ultimately improved consumer confidence.

The year 2009 has been make or break for many players in the industry, spelling the end of the road in the US for players such as Crabtree & Evelyn and brands such as Max Factor and Prescriptives (owned by Estee Lauder) .

However, Kline & Company industry analyst Carrie Mellage, believes that the worst could now be over for the personal care industry and that looking ahead some of the key growth areas for potential are about to get even more interesting.

You can read the full article here: Personal care market set for strong recovery in 2010.